Literature DB >> 27444940

Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T.

E J Meyer1, I I Kirov1, A Tal2, M S Davitz1, J S Babb1, M Lazar1, D Malaspina3, O Gonen4.   

Abstract

BACKGROUND AND
PURPOSE: Schizophrenia is well-known to be associated with hippocampal structural abnormalities. We used 1H-MR spectroscopy to test the hypothesis that these abnormalities are accompanied by NAA deficits, reflecting neuronal dysfunction, in patients compared with healthy controls.
MATERIALS AND METHODS: Nineteen patients with schizophrenia (11 men; mean age, 40.6 ± 10.1 years; mean disease duration, 19.5 ± 10.5 years) and 11 matched healthy controls (5 men; mean age, 33.7 ± 10.1 years) underwent MR imaging and multivoxel point-resolved spectroscopy (TE/TR, 35/1400 ms) 1H-MRS at 3T to obtain their hippocampal GM absolute NAA, Cr, Cho, and mIns concentrations. Unequal variance t tests and ANCOVA were used to compare patients with controls. Bilateral volumes from manually outlined hippocampal masks were compared by using unequal variance t tests.
RESULTS: Patients' average hippocampal GM Cr concentrations were 19% higher than that of controls, 8.7 ± 2.2 versus 7.4 ± 1.2 mmol/L (P < .05); showing no differences, concentrations in NAA were 8.8 ± 1.6 versus 8.7 ± 1.2 mmol/L; in Cho, 2.3 ± 0.7 versus 2.1 ± 0.3 mmol/L; and in mIns, 6.1 ± 1.5 versus 5.2 ± 0.9 (all P > .1). There was a positive correlation between mIns and Cr in patients (r = 0.57, P = .05) but not in controls. The mean bilateral hippocampal volume was ∼10% lower in patients: 7.5 ± 0.9 versus 8.4 ± 0.7 cm3 (P < .05).
CONCLUSIONS: These findings suggest that the hippocampal volume deficit in schizophrenia is not due to net loss of neurons, in agreement with histopathology studies but not with prior 1H-MR spectroscopy reports. Elevated Cr is consistent with hippocampal hypermetabolism, and its correlation with mIns may also suggest an inflammatory process affecting some cases; these findings may suggest treatment targets and markers to monitor them.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27444940      PMCID: PMC5161606          DOI: 10.3174/ajnr.A4886

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  42 in total

1.  Reducing voxel bleed in Hadamard-encoded MRI and MRS.

Authors:  Gadi Goelman; Songtao Liu; Oded Gonen
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

Review 2.  Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies.

Authors:  R Grant Steen; Courtney Mull; Robert McClure; Robert M Hamer; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2006-06       Impact factor: 9.319

3.  Selective Fourier transform localization.

Authors:  H R Brooker; T H Mareci; J T Mao
Journal:  Magn Reson Med       Date:  1987-11       Impact factor: 4.668

4.  Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T.

Authors:  Ivan I Kirov; Ilena C George; Nikhil Jayawickrama; James S Babb; Nissa N Perry; Oded Gonen
Journal:  Magn Reson Med       Date:  2011-06-07       Impact factor: 4.668

5.  The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging.

Authors:  Assaf Tal; Ivan I Kirov; Robert I Grossman; Oded Gonen
Journal:  NMR Biomed       Date:  2012-06-20       Impact factor: 4.044

6.  Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging.

Authors:  P Vermathen; K D Laxer; G B Matson; M W Weiner
Journal:  Radiology       Date:  2000-02       Impact factor: 11.105

7.  Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia.

Authors:  Jason R Tregellas; Jason Smucny; Josette G Harris; Ann Olincy; Keeran Maharajh; Eugene Kronberg; Lindsay C Eichman; Emma Lyons; Robert Freedman
Journal:  Am J Psychiatry       Date:  2014-05       Impact factor: 18.112

8.  Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Authors:  Iris E Sommer; Roos van Westrhenen; Marieke J H Begemann; Lot D de Witte; Stefan Leucht; René S Kahn
Journal:  Schizophr Bull       Date:  2013-10-08       Impact factor: 9.306

Review 9.  Neuroinflammation and psychiatric illness.

Authors:  Souhel Najjar; Daniel M Pearlman; Kenneth Alper; Amanda Najjar; Orrin Devinsky
Journal:  J Neuroinflammation       Date:  2013-04-01       Impact factor: 8.322

10.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium.

Authors:  T G M van Erp; D P Hibar; J M Rasmussen; D C Glahn; G D Pearlson; O A Andreassen; I Agartz; L T Westlye; U K Haukvik; A M Dale; I Melle; C B Hartberg; O Gruber; B Kraemer; D Zilles; G Donohoe; S Kelly; C McDonald; D W Morris; D M Cannon; A Corvin; M W J Machielsen; L Koenders; L de Haan; D J Veltman; T D Satterthwaite; D H Wolf; R C Gur; R E Gur; S G Potkin; D H Mathalon; B A Mueller; A Preda; F Macciardi; S Ehrlich; E Walton; J Hass; V D Calhoun; H J Bockholt; S R Sponheim; J M Shoemaker; N E M van Haren; H E H Pol; R A Ophoff; R S Kahn; R Roiz-Santiañez; B Crespo-Facorro; L Wang; K I Alpert; E G Jönsson; R Dimitrova; C Bois; H C Whalley; A M McIntosh; S M Lawrie; R Hashimoto; P M Thompson; J A Turner
Journal:  Mol Psychiatry       Date:  2015-08-18       Impact factor: 15.992

View more
  5 in total

1.  An integrative study of the microbiome gut-brain-axis and hippocampal inflammation in psychosis: Persistent effects from mode of birth.

Authors:  Peter Joe; Jose C Clemente; Enrica Piras; David S Wallach; Jessica Robinson-Papp; Emeka Boka; Brooke Remsen; Mharisi Bonner; David Kimhy; Deborah Goetz; Kevin Hoffman; Jakleen Lee; Eugene Ruby; Sarah Fendrich; Oded Gonen; Dolores Malaspina
Journal:  Schizophr Res       Date:  2021-10-06       Impact factor: 4.662

2.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.

Authors:  Matthijs G Bossong; Mathilde Antoniades; Matilda Azis; Carly Samson; Beverley Quinn; Ilaria Bonoldi; Gemma Modinos; Jesus Perez; Oliver D Howes; James M Stone; Paul Allen; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

3.  Preliminary Findings Associate Hippocampal 1H-MR Spectroscopic Metabolite Concentrations with Psychotic and Manic Symptoms in Patients with Schizophrenia.

Authors:  D Malaspina; E Lotan; H Rusinek; S A Perez; J Walsh-Messinger; T M Kranz; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-12       Impact factor: 3.825

4.  Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.

Authors:  Juan R Bustillo; Joel Upston; Elizabeth Grace Mayer; Thomas Jones; Andrew A Maudsley; Charles Gasparovic; Mauricio Tohen; Rhoshel Lenroot
Journal:  Neuropsychopharmacology       Date:  2020-05-13       Impact factor: 7.853

5.  The clinical utility of proton magnetic resonance spectroscopy in traumatic brain injury: recommendations from the ENIGMA MRS working group.

Authors:  Brenda L Bartnik-Olson; Jeffry R Alger; Talin Babikian; Ashley D Harris; Barbara Holshouser; Ivan I Kirov; Andrew A Maudsley; Paul M Thompson; Emily L Dennis; David F Tate; Elisabeth A Wilde; Alexander Lin
Journal:  Brain Imaging Behav       Date:  2021-04       Impact factor: 3.978

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.